LivaNova Plc LIVN

Tributary Capital Management released its second-quarter 2026 investor letter for “Multi Cap Core Equity Strategy”. You can download a copy of the letter here. The Tributary Multi Cap Core’s equity allocation underperformed in Q2, returning +12.5% against +15.3% for the S&P 1500 and +15.4% for the Russell 3000. Information Technology was the main driver of […]

GLOUCESTER, England, September 23, 2026--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2026 results on Wed., Nov. 4, 2026, at 1 p.m. Greenwich Mean Time (8 a.m. Eastern Standard Time). The Company will release its third-quarter 2026 results prior to the call.

Vivid brings over 30 years of operational and financial leadership in healthcare and life sciences, being a founder of LivaNova PLC, led OPEN Health as Interim Group CEO, and held senior roles at GlaxoSmithKline, Allergan, and LGCVivid will draw on his deep industry relationships and operational expertise to support GHO's portfolio companies directly, while also helping to expand the firm's network across the healthcare and life sciences sector London, UK – 8 September 2026: GHO Capital Partners

GLOUCESTER, England, September 03, 2026--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the two following September healthcare conferences in New York City:

LivaNova PLC recently reported second-quarter 2026 results showing sales rising to US$390.59 million and net income climbing to US$108.57 million, alongside higher earnings per share versus a year earlier. On the back of this performance, the company raised its 2026 constant-currency revenue growth guidance to a range of 8% to 9% and secured a long-term oxygenator supply agreement with Thermo Fisher Scientific to support manufacturing expansion. Now we’ll examine how the raised 2026 growth...

LivaNova (LIVN) raised its full year 2026 revenue and earnings guidance after reporting record quarterly revenue and significantly higher profitability, supported by demand for its Essenz heart-lung machine and a new supply agreement with Thermo Fisher Scientific. See our latest analysis for LivaNova. LivaNova's recent guidance lift comes after a strong run in the share price, with a 90 day share price return of 12.71% and a year to date share price return of 33.21%. The 1 year total...

Moby summary of LivaNova PLC's Q2 2026 earnings call

LivaNova PLC (LIVN) delivers 9.8% constant currency revenue growth, raises full-year outlook, and secures key oxygenator supply agreement.